rope01 rope02

About Us

Turning Point Therapeutics is a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies and improve the lives of patients.

Turning Point develops kinase inhibitors, a class of targeted cancer drugs, that are designed to bind to cancer cells with greater precision and affinity than existing therapies. Due in part to their compact structure and design, Turning Point’s kinase inhibitors have an ability to overcome common mechanisms of treatment resistance.

Our lead program, repotrectinib (TPX-0005), is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors including ROS1, NTRK, and ALK mutations. Based on preliminary clinical results in TKI-naïve and pre-treated patients, a registrational study of repotrectinib was initiated in the second half of 2019.


We are driven to develop therapies that mark a turning point for patients in their cancer treatment. Our team has extensive experience in the discovery, design and development of cancer therapeutics, with a clear focus on next-generation kinase inhibitors. Our president and chief executive officer, Dr. Athena Countouriotis, has led the development of multiple tyrosine kinase inhibitors (TKIs) through approval, including Sprycel (dasatinib), Sutent (sunitinib) and Bosulif (bosutinib). Our scientific founder, J. Jean Cui, Ph.D., was the lead inventor of two approved TKIs, Xalkori (crizotinib) and Lorbrena (lorlatinib).

ltBlueRP03 ltBlueRP02left ltBlueRP02left